Reuters -- Questions about effectiveness are the main issue surrounding Actelion Ltd’s (ATLN.VX) bid to sell a drug for treating a rare disease affecting the brain, U.S. drug reviewers said in documents released on Friday.
Reuters -- Questions about effectiveness are the main issue surrounding Actelion Ltd’s (ATLN.VX) bid to sell a drug for treating a rare disease affecting the brain, U.S. drug reviewers said in documents released on Friday.
